scholarly journals Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy

2018 ◽  
Vol 36 (7) ◽  
pp. 342.e7-342.e14 ◽  
Author(s):  
Brian R. Winters ◽  
Funda Vakar-Lopez ◽  
Lisha Brown ◽  
Bruce Montgomery ◽  
Roland Seiler ◽  
...  
Keyword(s):  
Protein Expression ◽  
Target Of Rapamycin ◽  
Mechanistic Target Of Rapamycin ◽  
Mtor Protein

scholarly journals Molecular docking of potential inhibitors with the mTOR protein

2021 ◽  
Vol 17 (1) ◽  
pp. 212-217
Author(s):  
JH Shazia Fathima ◽  
Keyword(s):  
Molecular Docking ◽  
Oral Cancer ◽  
Target Of Rapamycin ◽  
Mechanistic Target Of Rapamycin ◽  
Mtor Protein ◽  
Potential Inhibitors

The mTOR (mammalian or mechanistic Target of Rapamycin) is linked with oral cancer. Therefore, it is of interest to study the molecular docking-based binding of paclitaxel (a FDA approved drug for oral cancer) and its analogues with mTOR. Hence, we report the binding features of 10-Deacetyltaxol, 7-Epi-10-deacetyltaxol, 7-Epi-Taxol and 6alpha-Hydroxypaclitaxel with mTOR for further consideration.

scholarly journals Mechanistic Target of Rapamycin Complex 2 Regulation of the Primary Human Trophoblast Cell Transcriptome

2021 ◽  
Vol 9 ◽  
Author(s):  
Fredrick J. Rosario ◽  
Amy Catherine Kelly ◽  
Madhulika B. Gupta ◽  
Theresa L. Powell ◽  
Laura Cox ◽  
...  
Keyword(s):  
Protein Expression ◽  
Gene Array ◽  
Target Of Rapamycin ◽  
Human Trophoblast ◽  
Mechanistic Target Of Rapamycin ◽  
Expression Of Genes ◽  
Genes Encoding ◽  
Cell Transcriptome ◽  
Pathway Analyses

Mechanistic Target of Rapamycin Complex 2 (mTORC2) regulates placental amino acid and folate transport. However, the role of mTORC2 in modulating other placental functions is largely unexplored. We used a gene array following the silencing of rictor to identify genes regulated by mTORC2 in primary human trophoblast (PHT) cells. Four hundred and nine genes were differentially expressed; 102 genes were down-regulated and 307 up-regulated. Pathway analyses demonstrated that inhibition of mTORC2 resulted in increased expression of genes encoding for pro-inflammatory IL-6, VEGF-A, leptin, and inflammatory signaling (SAPK/JNK). Furthermore, down-regulated genes were functionally enriched in genes involved in angiogenesis (Osteopontin) and multivitamin transport (SLC5A6). In addition, the protein expression of leptin, VEGFA, IL-6 was increased and negatively correlated to mTORC2 signaling in human placentas collected from pregnancies complicated by intrauterine growth restriction (IUGR). In contrast, the protein expression of Osteopontin and SLC5A6 was decreased and positively correlated to mTORC2 signaling in human IUGR placentas. In conclusion, mTORC2 signaling regulates trophoblast expression of genes involved in inflammation, micronutrient transport, and angiogenesis, representing novel links between mTOR signaling and multiple placental functions necessary for fetal growth and development.

scholarly journals Lysosomes, Autophagy, and Hormesis in Cell Physiology, Pathology, and Age-Related Disease

Dose-Response ◽  
2020 ◽  
Vol 18 (3) ◽  
pp. 155932582093422 ◽  
Author(s):  
Michael N. Moore
Keyword(s):  
Intracellular Signaling ◽  
Adenosine Monophosphate ◽  
Target Of Rapamycin ◽  
Cell Physiology ◽  
Mechanistic Target Of Rapamycin ◽  
Age Related ◽  
Mechanistic Basis ◽  
The Many ◽  
Mtor Complex 1

Autophagy has been strongly linked with hormesis, however, it is only relatively recently that the mechanistic basis underlying this association has begun to emerge. Lysosomal autophagy is a group of processes that degrade proteins, protein aggregates, membranes, organelles, segregated regions of cytoplasm, and even parts of the nucleus in eukaryotic cells. These degradative processes are evolutionarily very ancient and provide a survival capability for cells that are stressed or injured. Autophagy and autophagic dysfunction have been linked with many aspects of cell physiology and pathology in disease processes; and there is now intense interest in identifying various therapeutic strategies involving its regulation. The main regulatory pathway for augmented autophagy is the mechanistic target of rapamycin (mTOR) cell signaling, although other pathways can be involved, such as 5′-adenosine monophosphate-activated protein kinase. Mechanistic target of rapamycin is a key player in the many highly interconnected intracellular signaling pathways and is responsible for the control of cell growth among other processes. Inhibition of mTOR (specifically dephosphorylation of mTOR complex 1) triggers augmented autophagy and the search is on the find inhibitors that can induce hormetic responses that may be suitable for treating many diseases, including many cancers, type 2 diabetes, and age-related neurodegenerative conditions.

Infektionen unter Immunsuppression nach Nierentransplantation

2020 ◽  
Vol 24 (08) ◽  
pp. 309-318
Author(s):  
Stephan Kemmner ◽  
Ulf Schönermarck
Keyword(s):  
Mtor Inhibitor ◽  
Pneumocystis Jirovecii ◽  
Target Of Rapamycin ◽  
Virale Infektionen ◽  
Mechanistic Target Of Rapamycin ◽  
Nach Transplantation ◽  
Polyomavirus Bk ◽  
Prophylaktische Therapie

ZUSAMMENFASSUNGUnter immunsuppressiver Therapie besteht ein deutlich erhöhtes Infektionsrisiko nach Nierentransplantation (NTx), insbesondere für virale Infektionen. Bereits vor einer geplanten NTx sollte auf einen aktuellen Impfstatus geachtet werden, da nach einer Transplantation unter immunsuppressiver Therapie einerseits Lebendimpfstoffe nicht mehr gegeben werden dürfen und andererseits eine adäquate Impfantwort schwieriger zu erreichen ist. Die saisonale Influenzaimpfung kann bereits einen Monat nach Transplantation gegeben werden, für alle anderen Impfungen wird ein Abwarten von 3–6 Monaten empfohlen. Eine prophylaktische Therapie kann das Auftreten bestimmter Infektionen effektiv verhindern. Nach NTx sollte für die ersten 6 Monate eine PjP-Prophylaxe (PjP: Pneumocystis-jirovecii-Pneumonie) mit Trimethoprim/Sulfamethoxazol verabreicht werden. Eine CMV-Prophylaxe (CMV: Zytomegalievirus) mit Valganciclovir erfolgt in Abhängigkeit vom Sero-Status von Empfänger und Spender i. d. R. für 3 bzw. 6 Monate. Im Falle einer Infektion kann in Abhängigkeit vom Schweregrad der Antimetabolit (meist MMF: Mycophenolatmofetil) dosishalbiert oder pausiert werden, jedoch ist dies mit einem erhöhten Rejektionsrisiko verbunden. Insbesondere bei Infektionen mit CMV und BKV (Polyomavirus BK) kann anstelle von MMF ein mTOR-Inhibitor (mTOR: „mechanistic target of rapamycin“) eingesetzt werden in Kombination mit einem niedrigdosierten Calcineurininhibitor (CNI). Bei einer COVID-19-Erkrankung (COVID-19: Coronavirus Disease 2019) nach NTx sollte wie bei anderen Infektionen in einer Kombinationstherapie zunächst der Antimetabolit bzw. der mTOR-Inhibitor dosisreduziert oder pausiert werden. Ein Absetzen des CNIs bei COVID-19 erscheint aus unserer Sicht nicht regelhaft indiziert, sondern bleibt schweren Verläufen im Einzelfall vorbehalten. Im Falle einer antiviralen Therapie bei COVID-19 muss immer an mögliche Interaktionen mit den Immunsuppressiva (v. a. mit CNI und mTOR-Inhibitoren) gedacht werden.

Histological and Immunohistochemical Evaluation of Phosphorylated Mechanistic Target of Rapamycin in Canine Skin Tumours

2021 ◽  
Vol 184 ◽  
pp. 60-64
Author(s):  
Raimon Mathew ◽  
Indira S. Sajitha ◽  
Dhanush K. Balakrishnan-Nair ◽  
Sudheesh S. Nair ◽  
Bibu J. Kariyil ◽  
...  
Keyword(s):  
Target Of Rapamycin ◽  
Skin Tumours ◽  
Mechanistic Target Of Rapamycin
Sign in / Sign up

Export Citation Format

Share Document